Amyloidosis: A rare disease with varied manifestations
Amyloidosis is a disease characterized by abnormal deposition of aggregated interstitial fibrils of amyloid protein in any organ of the human body, resulting in compromised organ function leading to a potentially fatal outcome. The most common type, systemic light-chain amyloidosis, amyloid light-chain (AL) amyloidosis, is a disorder due to clonal plasma cell dyscrasia. The varied presentations usually present challenges in diagnosis, treatment, and overall management of these patients requiring a multidisciplinary management. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - August 31, 2016 Category: Cancer & Oncology Authors: Beata Holkova Source Type: research
Renal Amyloidosis
Amyloidosis is a rare disease caused by extracellular deposition of proteins in an insoluble beta-pleated physical conformation. Multiple causative proteins have been identified in amyloidosis, all leading to a similar alteration in structural change leading to extracellular deposition of fibrils. The kidney is a common site of amyloid deposition in AL, AA and the hereditary amyloidosis. Amyloid kidney can be difficult to recognize because of its subtle presentation and insidious progression. In fact, most cases of amyloidosis are diagnosed after recognition of multi-organ dysfunction, including: heart failure, renal insuf...
Source: Current Problems in Cancer - August 29, 2016 Category: Cancer & Oncology Authors: Jason Kidd, Daniel E. Carl Tags: Amyloidosis and its management Source Type: research
Amyloidosis and its management: Amyloid neuropathies
The amyloid neuropathies are rare but fatal, rapidly progressive systemic disorders that often are misdiagnosed when initially presenting as a peripheral neuropathy.1 Light chain, or AL amyloidosis, an acquired disorder, and familial amyloid polyneuropathy, a hereditary disorder, may each cause severe and disabling peripheral neuropathies, in addition to other systemic manifestations. Diagnosis may be delayed, especially in the familial amyloid neuropathies, based on atypical presentation, late-onset, or lack of positive family history. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - August 29, 2016 Category: Cancer & Oncology Authors: Kathleen Thornton Pearson, Scott Vota Source Type: research
Toxicities associated with head and neck cancer treatment and oncology-related clinical trials
Approximately 600,000 new cases of head and neck cancer (HNC) would be diagnosed worldwide this year. Of those, a bit less than 10% would occur in the United States.1 Most of these neoplasms would be histologically diagnosed as squamous cell carcinomas for which the preferred treatment typically consists of a multimodality approach that includes local resection followed by a course of concomitant chemoradiation in which radiosensitizing chemotherapy (most commonly cisplatin) is coupled with cumulative radiation doses of 60-70Gy given in 1.8-2.2Gy daily fractions. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - June 16, 2016 Category: Cancer & Oncology Authors: Alessandro Villa, Stephen Sonis Source Type: research
Toxicities Associated with Head and Neck Cancer Treatment and Oncology-Related Clinical Trials
Approximately 600,000 new cases of head and neck cancer will be diagnosed worldwide this year. Of those, a bit less than 10% will occur in the United States.1 The majority of these neoplasms will be histologically diagnosed as squamous cell carcinomas for which the preferred treatment typically consists of a multi-modality approach which includes local resection followed by a course of concomitant chemoradiation in which radiosensitizing chemotherapy (most commonly cisplatin) is coupled with cumulative radiation doses of 60Gy – 70Gy given in 1.8Gy – 2.2Gy daily fractions. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - June 16, 2016 Category: Cancer & Oncology Authors: Alessandro Villa, Stephen Sonis Source Type: research
Giving another chance to mifepristone in pharmacotherapy for aggressive meningiomas —A likely synergism with hydroxyurea?
Meningiomas are the most frequently reported intracranial tumors, accounting for approximately one-fourth of all reported primary brain neoplasms.1 They are benign in approximately 90% of the cases and the remaining cases are either borderline or atypical (World Health Organization [WHO] grade II) or malignant (WHO grade III).1 In the United States, the incidence rates with similar age standardization estimated from figures provided by the Central Brain Tumor Registry were 1.8 for men and 4.2 per 100,000 for women in 2006. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - May 15, 2016 Category: Cancer & Oncology Authors: İlhan Elmaci, Meric A. Altinoz, Aydin Sav, Zeliha Yazici, Aysel Ozpinar Source Type: research
Giving another chance to mifepristone in pharmacotherapy for aggressive meningiomas—A likely synergism with hydroxyurea?
Meningiomas are the most frequently reported intracranial tumors, accounting for approximately one-fourth of all reported primary brain neoplasms.1 They are benign in approximately 90% of the cases and the remaining cases are either borderline or atypical (World Health Organization [WHO] grade II) or malignant (WHO grade III).1 In the United States, the incidence rates with similar age standardization estimated from figures provided by the Central Brain Tumor Registry were 1.8 for men and 4.2 per 100,000 for women in 2006. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - May 15, 2016 Category: Cancer & Oncology Authors: İlhan Elmaci, Meric A. Altinoz, Aydin Sav, Zeliha Yazici, Aysel Ozpinar Source Type: research
Giving another chance to mifepristone in pharmacotherapy of aggressive meningiomas. A likely synergism with hydroxyurea?
High grade meningiomas (HGM) are relatively rare, yet their fatal course constitutes a significant health problem. Pharmacological options include hydroxyurea (HU), somatostatin and IFN-alpha. HU inhibits ribonucleotide reductase subunit 2 (RRM2) and thereby DNA synthesis and its dose-limiting toxicity is myelosuppression. During embryogenesis, RRM2 is specifically induced by progesterone in uterine implantation sites. Meningioma growth is stimulated with pregnancy and exogenous progesterone analogues. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - May 15, 2016 Category: Cancer & Oncology Authors: İlhan Elmacı, Meric A. Altinoz, Aydin Sav, Zeliha Yazici, Aysel Ozpinar Source Type: research
Title page
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - January 1, 2016 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - January 1, 2016 Category: Cancer & Oncology Source Type: research
Title page
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - December 31, 2015 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - December 31, 2015 Category: Cancer & Oncology Source Type: research
Foreword
Anecdotal evidence for the abscopal effect of radiation therapy has garnered significant interest in recent years. It was recognized early on that the abscopal effect was likely mediated through activation of tumor specific immune responses, but its therapeutic application limited. Until recently, the abscopal effect remained an interesting but rare clinical entity, and endeavors to exploit this effect with cytokine based immunotherapy or cancer vaccines have met with limited success. Recent paradigm shift in cancer immunotherapy with unprecedented response rates demonstrated by immune checkpoint inhibitors targeting CTLA4...
Source: Current Problems in Cancer - December 28, 2015 Category: Cancer & Oncology Authors: Sungjune Kim Source Type: research
